<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575806</url>
  </required_header>
  <id_info>
    <org_study_id>CancerIHCAMS-HCC-Tcm</org_study_id>
    <nct_id>NCT03575806</nct_id>
  </id_info>
  <brief_title>Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection</brief_title>
  <official_title>A Single-center, Open-label, Exploratory Trial of Autologous Immunotherapy for Hepatocellular Carcinoma (HCC) With Microvascular Invasion (MVI) After Radical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newish Technology (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of combining autologous Tcm
      immunotherapy and TACE in HCC patients with MVI after radical resection. Patients will be
      assigned either to the experimental arm to receive autologous Tcm immunotherapy and TACE or
      to the active comparator (TACE alone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is one of the common cancer worldwide, which is the third
      cause of cancer related deaths. Radical hepatic resection remains the main treatment for
      hepatocellular carcinoma, the 5-year survival rate of HCC after surgery was 60-70%.
      Unfortunately, HCC is prone to postoperative recurrence that more than 50% of patients
      relapse within 2 years, which has become the key to restrict the therapeutic effect of
      hepatocellular carcinoma. Microvascular invasion (MVI) is one of the main risk factors for
      poor prognosis in HCC.

      Autologous cell immunotherapy is to collect patient's own immune cells and then given back to
      the patient after amplified in vitro that can improve the anti-tumor immune response. Tcm
      (central memory T cells) are effective anti-tumor immune cells that exhibit the long-term
      survival and self-renewal capacity in vivo. Autologous Tcm immunotherapy combining
      chemotherapy, surgery or radiotherapy would effectively prolong survival period, prevent
      tumor recurrence and metastasis, then improve quality of life in patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free Survival (RFS) Time</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence-free survival was defined as the interval (in months) between hepatectomy and diagnosis of recurrence using either intrahepatic recurrence or extrahepatic metastasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival rate = the number of patients in TACE/TACE+Tcm group survived at 24 months/the number of total patients assigned into TACE/TACE+Tcm group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>TACE+Tcm group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator: TACE to treat HCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TACE plus autologous Tcm immunotherapy</intervention_name>
    <description>TACE:transcatheter arterial chemoembolization.
Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro.</description>
    <arm_group_label>TACE+Tcm group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE:transcatheter arterial chemoembolization.</description>
    <arm_group_label>TACE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be willing and able to provide written informed consent for the study.

          2. Subject has accepted radical hepatic resection, and preoperative imaging is no
             vascular invasion.

          3. Postoperative pathology confirmed Hepatocellular carcinoma with negative margin and
             microvascular invasion (MVI).

          4. Age between 18-75 years old.

          5. Radiology confirmed complete response (CR) after radical surgery.

          6. Child-Pugh A.

          7. Eastern Cooperative Oncology Group(ECOG) body condition score 0.

          8. Adequate hepatic and renal function:

             Hemoglobin ≥ 9.0g/dl. Absolute neutrophil count (ANC) &gt; 1,500/mm3. Platelets ≥
             50,000/ul. Total bilirubin (TBIL) ≤ 2mg/dl. Alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) ≤ 5 the upper limit of normal (ULN) for the
             institution.

             Alkaline phosphatase (ALP) ≤ 4 the upper limit of ULN. Prothrombin time (PT) &gt; 50% or
             prothrombin time-international normalized ratio (PT-INR) &lt; 2.3.

             Serum creatinine (CREA) ≤ 1.5 the upper limit of ULN.

          9. Female subjects have had a negative blood pregnancy test within 2 week,

         10. Subjects be willing to use appropriate contraception during the trial and 2 weeks
             after the last administration of immunotherapy.

         11. Radiology such as CT and MRI were performed in 4 weeks before the study.

        Exclusion Criteria:

          1. Recurrent HCC.

          2. Portal vein embolus.

          3. Cardiovascular disease:

             Evidence of NYHA functional class III or IV heart disease. Unstable coronary artery
             disease (CAD) is not allowed, while Myocardial Infarction (MI) 6 months of starting
             study is allowed.

             Cardiac arrhythmias requiring antiarrhythmic drugs except β-blockers or digoxin are
             not allowed.

             Uncontrolled hypertension.

          4. History of Human Immunodeficiency Virus (HIV) or syphilis infection.

          5. Severe inflammation, NCI CTCAE Version 3.0 grade &gt; 2.

          6. Epilepsy requiring steroid or antiepileptic drugs.

          7. History of allotransplantation.

          8. History or any evidence of hemorrhage.

          9. Subjects undergoing renal dialysis.

         10. Pregnancy or breast-feeding.

         11. Prior or undergoing cancers that primary sites are different from the carcinoma of
             this study. Exceptions to this are:

             Cervical carcinoma in situ (CIS) Cured basal cell carcinoma Superficial bladder tumor
             Cured cancers over 3 years before the study

         12. Uncontrolled Ascites by diuretic treatment.

         13. History of encephalopathy.

         14. Gastrointestinal hemorrhage in 30 days before the study.

         15. History of esophageal variceal hemorrhage and it is no effective treatment to prevent
             the recurrence of hemorrhage.

         16. Major surgery except radical hepatic resection was performed in 4 weeks before the
             study.

         17. Autologous bone marrow transplantation (ABMT) in 4 weeks before the study.

         18. Concurrent treatment on another clinical trial or treatment on another clinical trial
             in 4 weeks before the study.

         19. Drug abuse, medical treatment, mental illness or social disorders that would interfere
             with subjects' participation, or confound the results of the trial.

         20. Any condition that would interfere with or endanger the safety and compliance of
             subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Zhao</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <results_first_submitted>December 5, 2019</results_first_submitted>
  <results_first_submitted_qc>May 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Hong Zhao</investigator_full_name>
    <investigator_title>assistant director physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03575806/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study was not of a randomized design, patients were recruited by their willingness to receive the Tcm transfusion as the adjuvant therapy after screening and meeting the eligibility criteria. As pathological classification with MVI was determined after 1 week postoperatively, patients consented with radical operation would be screened again.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TACE Group</title>
          <description>Control arm: only TACE
(TACE: transcatheter arterial chemoembolization)</description>
        </group>
        <group group_id="P2">
          <title>TACE+Tcm Group</title>
          <description>Experimental arm: TACE plus autologous Tcm immunotherapy
(TACE:transcatheter arterial chemoembolization)
Autologous Tcm immunotherapy: collected patient's own immune cells and then transfused back to patient after being amplified in vitro.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per Protocol Set (PPS):
Be eligiable for inclusion criterial and exclusion criterial;
Complete the whole follow-up program;
Refuse other therapies for HCC in the follow-up program which would influence the efficacy evaluation of Tcm.</population>
      <group_list>
        <group group_id="B1">
          <title>TACE Group</title>
          <description>Control arm: only TACE
(TACE: transcatheter arterial chemoembolization)</description>
        </group>
        <group group_id="B2">
          <title>TACE+Tcm Group</title>
          <description>Experimental arm: TACE plus autologous Tcm immunotherapy
(TACE:transcatheter arterial chemoembolization)
Autologous Tcm immunotherapy: collected patient's own immune cells and then transfused back to patient after being amplified in vitro.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" lower_limit="27" upper_limit="68"/>
                    <measurement group_id="B2" value="53.7" lower_limit="31" upper_limit="77"/>
                    <measurement group_id="B3" value="53.5" lower_limit="27" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group(ECOG)</title>
          <description>ECOG STATUS
0, Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>ECOG=0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG=1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence-free Survival (RFS) Time</title>
        <description>Recurrence-free survival was defined as the interval (in months) between hepatectomy and diagnosis of recurrence using either intrahepatic recurrence or extrahepatic metastasis.</description>
        <time_frame>12 months</time_frame>
        <population>PPS (Per Protocol Set)</population>
        <group_list>
          <group group_id="O1">
            <title>TACE Group</title>
            <description>Control arm: only TACE
(TACE: transcatheter arterial chemoembolization)</description>
          </group>
          <group group_id="O2">
            <title>TACE+Tcm Group</title>
            <description>Experimental arm: TACE plus autologous Tcm immunotherapy
(TACE:transcatheter arterial chemoembolization)
Autologous Tcm immunotherapy: collected patient's own immune cells and then transfused back to patient after being amplified in vitro.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival (RFS) Time</title>
          <description>Recurrence-free survival was defined as the interval (in months) between hepatectomy and diagnosis of recurrence using either intrahepatic recurrence or extrahepatic metastasis.</description>
          <population>PPS (Per Protocol Set)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="3.99"/>
                    <measurement group_id="O2" value="12" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate at 24 Months</title>
        <description>Overall survival rate = the number of patients in TACE/TACE+Tcm group survived at 24 months/the number of total patients assigned into TACE/TACE+Tcm group.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TACE Group</title>
            <description>Control arm: only TACE
(TACE: transcatheter arterial chemoembolization)</description>
          </group>
          <group group_id="O2">
            <title>TACE+Tcm Group</title>
            <description>Experimental arm: TACE plus autologous Tcm immunotherapy
(TACE:transcatheter arterial chemoembolization)
Autologous Tcm immunotherapy: collected patient's own immune cells and then transfused back to patient after being amplified in vitro.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Rate at 24 Months</title>
          <description>Overall survival rate = the number of patients in TACE/TACE+Tcm group survived at 24 months/the number of total patients assigned into TACE/TACE+Tcm group.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Survival</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Laboratory examination of blood tests, liver and kidney function of all patients were collected every 4 weeks during Tcm treatment and every 12 weeks after Tcm treatment in 48 weeks or ended the last follow-up. 1 patients assigned into TACE+Tcm group requested withdrawing without any administration of Tcm.</desc>
      <group_list>
        <group group_id="E1">
          <title>TACE Group</title>
          <description>Control arm: only TACE
(TACE: TACE:transcatheter arterial chemoembolization)</description>
        </group>
        <group group_id="E2">
          <title>TACE+Tcm Group</title>
          <description>Experimental arm: TACE plus autologous Tcm immunotherapy
(TACE:transcatheter arterial chemoembolization)
Autologous Tcm immunotherapy: collected patient's own immune cells and then transfused back to patient after being amplified in vitro.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <description>patients with decreasing white blood cells or lymphocytes</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <description>Patients with total bilirubin or ALT or AST elevation</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was a pilot study with small sample size, which would influence the statistical results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Statistician of Clinical Trials</name_or_title>
      <organization>Tsinghua University</organization>
      <email>majunfan2@sina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

